- Sections
- C - Chimiemétallurgie
- C08B - Polysaccharidesleurs dérivés
- C08B 37/10 - HéparineSes dérivés
Détention brevets de la classe C08B 37/10
Brevets de cette classe: 155
Historique des publications depuis 10 ans
|
4
|
11
|
5
|
6
|
3
|
5
|
3
|
5
|
7
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Agency for Science, Technology and Research | 3584 |
11 |
| Momenta Pharmaceuticals, Inc. | 289 |
9 |
| Laboratorios Farmaceuticos Rovi, S.A. | 236 |
8 |
| Sanofi | 4009 |
8 |
| Rensselaer Polytechnic Institute | 823 |
4 |
| Suzhou Ronnsi Pharma Co., Ltd. | 6 |
4 |
| sanofi-aventis | 374 |
4 |
| Tsinghua University | 5840 |
3 |
| Cantex Pharmaceuticals, Inc. | 24 |
3 |
| Dilafor AB | 19 |
3 |
| Dilaforette AB | 3 |
3 |
| Seikagaku Corporation | 189 |
3 |
| Shandong University | 1020 |
3 |
| The University of North Carolina at Chapel Hill | 2025 |
3 |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | 14 |
3 |
| Ajinomoto Co., Inc. | 2298 |
2 |
| The Board of Regents of the University of Oklahoma | 608 |
2 |
| Cisen Pharmaceutical Co., Ltd. | 25 |
2 |
| Glytech, Inc. | 65 |
2 |
| National University Corporation Chiba University | 491 |
2 |
| Autres propriétaires | 73 |